The role of the C-terminal domain in the inhibitory functions of tissue factor pathway inhibitor  by Ettelaie, Camille et al.
The role of the C-terminal domain in the inhibitory functions of
tissue factor pathway inhibitor
Camille Ettelaie*, Jacqueline M. Adam, Nicola J. James, Adedayo O. Oke,
Jillian A. Harrison, Tim D. Bunce, K. Richard Bruckdorfer
Department of Biochemistry and Molecular Biology, Royal Free and University College Medical School (Royal Free Campus),
Rowland Hill Street, London NW3 2PF, UK
Received 9 November 1999
Edited by Marco Baggiolini
Abstract Tissue factor pathway inhibitor (TFPI) inhibits the
activity of coagulation factors VIIa and Xa through Kunitz
domains, thereby inhibiting the activity of tissue factor.
However, it has been shown that the C-terminal of this inhibitor
is essential for the maximal anticoagulant activity of TFPI. We
have investigated the endogenous ability of the C-terminal of
TFPI to influence coagulation. A synthetic peptide corresponding
to residues 254^265 within the C-terminal of TFPI was prepared
and shown to be capable of inhibiting tissue factor pathway by
preventing the activation of factor VII. Mutational analysis of
the peptide revealed the identity of the key lysine residues.
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1. Introduction
The exposure of tissue factor upon injury to the endothe-
lium initiates the extrinsic pathway of coagulation [1,2]. The
ability of the tissue factor pathway inhibitor (TFPI) to inhibit
the extrinsic pathway of coagulation has been clearly demon-
strated [3,4]. TFPI contains three tandem Kunitz domains, the
¢rst two inhibiting factors VIIa and Xa, respectively [4]. Se-
quencing of the TFPI cDNA revealed that TFPI encompasses
a highly basic C-terminal domain containing repeated lysine
and arginine residues [5]. The C-terminal peptide of TFPI has
been shown to be involved in the optimal activity of TFPI
[6,7]. Furthermore, it has been demonstrated that, while the
full-length TFPI and C-terminal truncated TFPI have similar
potencies to inhibit factor Xa, the quaternary complex tissue
factor-factor VIIa-TFPI-factor Xa is much more stable in the
presence of full-length TFPI [8]. This indicated further that
interactions occur between the C-terminal of TFPI and tissue
factor-factor VIIa complex. In our previous work, we demon-
strated that the function of full-length TFPI which associates
with LDL is suppressed upon induction of oxidation [9]. Con-
versely, C-terminal truncated TFPI was una¡ected by the
treatment. Moreover, the non-speci¢c chemical modi¢cation
of arginine and particularly lysine residue drastically reduced
the e¡ectiveness of TFPI [9]. We have now demonstrated a
novel anticoagulant activity of a peptide (residues 254^265)
within the C-terminal of TFPI, which inhibits the tissue factor
and prothrombinase complex independently of the Kunitz
domains, and have identi¢ed the key residues required for
this activity which include basic amino acids. We propose,
therefore, an explanation for the disparity in the abilities of
full-length and C-terminal truncated TFPI to inhibit the ex-
trinsic pathway of coagulation.
2. Material and methods
2.1. Preparation of synthetic peptide, mutants and controls
Solid phase peptide synthesis was carried out according to estab-
lished methods [10], but using O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetra-
methyluronium hexa£uorophosphate (PerSeptive Biosystems, Herts,
UK) for superior coupling and to minimise racemisation [11]. In ad-
dition, peptides were synthesised to order (Genosys Biotechnologies,
Cambridge, UK). The peptides included the wild-type (WT) (KTK-
RKRKKQRVK) and mutants containing Ala substitutions in each of
the 12 positions (N- to C-terminal), in turn (Mut 1^12). The synthes-
ised peptides were analysed for molecular weight and purity by mass
spectroscopy and high performance liquid chromatography. Due to
the proportion of positively charged amino acids (nine out of 12)
within the sequence, no attempt was made to produce reverse or
scrambled variants of the peptide. Instead, control peptides were pre-
pared with high proportions of basic amino acids (SHRHK-
NKKSAQK and KAHSKTRSKTHNQK) or purchased which were
poly-L-lysine, poly-L-arginine, control peptide (TRLTRKRGLKLA-
TAL) (Sigma Chemical Company, Poole, UK).
2.2. Measurement of tissue factor activity
Tissue factor activity was measured using both the one-stage pro-
thrombin time assay and an amidolytic assay as described previously
[12] and the percentage inhibition calculated. In some experiments,
factors VII and X were pre-incubated with the samples prior to assay.
The two-stage amidolytic assay was carried out according to pub-
lished procedures [13] using N-benzoyl-Phe-Val-Arg-p-nitroanilide ob-
tained from (Sigma Chemical Company, Poole, UK). Also, in a var-
iation factor Xa activity was measured using N-benzoyl-Ile-Glu-Gly-
Arg-p-nitroanilide. To test the e¡ects of the various peptides, they
were pre-incubated, over a range of concentrations (0^500 nM) with
tissue factor for 0^40 min before application of either method. The
tissue factor activity was then calculated from a standard curve and
the percentage inhibition due to the peptide being tested was calcu-
lated. Finally, a similar experiment was carried out, but the peptide
(100, 150 and 200 nM ¢nal concentration) was incubated with PMA-
treated THP-1 cells exhibiting activity [14] equivalent to 50 nM re-
combinant tissue factor.
2.3. Measurement of thrombin, factor Xa, factor V and VII activity/
activation
The ability of the TFPI254ÿ265 peptide (0^500 nM) or control pep-
tides to in£uence the enzymatic and procoagulant activity of throm-
bin, factor X (Sigma Chemical Company, Poole, UK) and V (Diag-
nostic Reagents Oxon, UK) were assessed as described previously [12].
Furthermore, the e¡ect of the TFPI254ÿ265 peptide on factor VIIa
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activity and factor VII (Sigma Chemical Company, Poole, UK) acti-
vation was investigated according to the procedure previously de-
scribed [12].
2.4. Statistical analysis
Data were expressed as means and S.E.M. for at least three experi-
ments, unless otherwise stated. The signi¢cance values were obtained
using unpaired Student’s t-test. Except where stated, the data were
comparable for both the one-stage prothrombin time assay and two-
stage amidolytic assay.
3. Results
3.1. E¡ects of TFPI254ÿ265 peptide on tissue factor activity
Incubation of TFPI254ÿ265 peptide (0^500 nM) with tissue
factor (200 nM) at 37‡C produced a concentration-dependent
inhibition of the procoagulant activity (Fig. 1). The control
peptides, poly-lysine, poly-arginine, a synthetic basic peptide
(TRLTRKRGLKLATAL) and two other recombinant basic
peptides (TTSHRHKNKKSAQK and KAHSKTRSKTH-
NQK) showed no inhibitory activity against tissue factor, in-
dicating that the e¡ects of TFPI254ÿ265 peptide are sequence
speci¢c and not a general e¡ect of basic peptides. Time-course
studies using 500 nM TFPI254ÿ265 peptide indicated that an
inhibition of s 95% was attained following 15 min pre-incu-
bation (Fig. 1). Moreover, the presence of either factor VIIa,
Xa or CaCl2 was not a pre-requisite to the inhibitory action
by TFPI254ÿ265 peptide. When used against activated cells, the
peptide exhibited a comparable concentration-dependent in-
hibition of the procoagulant activity (Fig. 2).
3.2. Mutational analysis of TFPI254ÿ265 peptide
The alanine substitution of all 12 amino acids in
TFPI254ÿ265 peptide revealed a number of key inhibitory ami-
no acids within the peptide sequence, as well as identifying the
non-participating amino acids (Table 1). Mutation of lysine
residues at positions 3, 5, 7, 8 and 12 (representing positions
256, 258, 260, 261 and 265 in TFPI) or the glutamine at
position 9 (262 in TFPI) reduced the inhibitory potential of
the peptide by over 65%, with the lysines 7 and 8 being the
most important residues.
3.3. Measurement of in£uence of TFPI254ÿ265 peptide on
thrombin, factor Xa and factor V activity
Pre-incubation of the TFPI254ÿ265 peptide (500 nM) with
thrombin did not a¡ect either the clotting ability or the ami-
dolytic proteolytic activity of the latter (100 nM) (not shown).
The TFPI254ÿ265 peptide (500 nM) also did not a¡ect the
amidolytic activity of factor Xa (not shown), indicating that
it does not interfere with enzymatic action of this clotting
factor. However, some inhibition of coagulation was observed
upon pre-incubation of TFPI254ÿ265 peptide (500 nM) with
either factor Xa (100 nM) or factor V (1 WM) (Fig. 3), indi-
cating some interference with prothrombinase complex assem-
bly. This was also repeated with two lower concentrations of
TFPI254ÿ265 peptide (100 and 200 nM) and inhibition was also
observed. Hence, the ability of TFPI254ÿ265 peptide to inhibit
the clotting activity, but not the enzymatic activity of factor
Xa, suggests that the peptide interferes with the interactions
Table 1
The in£uence of alanine mutations of TFPI254ÿ265 peptide
Peptide Sequence Procoagulant activity % Inhibition
Control ^ 50 U/ml þ 5 0%
WT KTKRKRKKQRVK 0.5 U/ml þ 3* 99%
M1 ATKRKRKKQRVK 7.8 U/ml þ 4*V 84%
M2 KAKRKRKKQRVK 2.5 U/ml þ 4* 95%
M3 KTARKRKKQRVK 36 U/ml þ 52 28%
M4 KTKAKRKKQRVK 2.5 U/ml þ 2* 95%
M5 KTKRARKKQRVK 32.5 U/ml þ 42 35%
M6 KTKRKAKKQRVK 7.5 U/ml þ 3*V 85%
M7 KTKRKRAKQRVK 40 U/ml þ 52 20%
M8 KTKRKRKAQRVK 36.5 U/ml þ 52 27%
M9 KTKRKRKKARVK 32 U/ml þ 22 36%
M10 KTKRKRKKQAVK 10 U/ml þ 4*V 80%
M11 KTKRKRKKQRAK 0.3 U/ml þ 2* 99%
M12 KTKRKRKKQRVA 35 U/ml þ 52 30%
Samples of TFPI254ÿ265 peptide and 12 mutant peptides (500 nM) were incubated with tissue factor (50 nM (50 arbitrary units/ml)) at 37‡C for
10 min prior to assaying. The activity was calculated from a tissue factor standard curve. The data were expressed as mean þ S.E.M., obtained
from three independent experiments. Statistical analysis carried out by t-test. * Ps 0.01 against control (no peptide), 2 Ps 0.01, V Ps 0.05
against WT TFPI254ÿ265 peptide.
Fig. 1. Time-course assay of the inhibition of the procoagulant ac-
tivity of recombinant tissue factor by TFPI254ÿ265 peptide. Three
1 ml samples of TFPI254ÿ265 peptide (100 (8), 200 (R) and 500 (F)
nM) were incubated with recombinant human tissue factor (200 nM)
and samples were removed at various times up to 40 min and as-
sayed. Control peptides were also included in the assay (not shown).
The percentage inhibition of tissue factor activity was calculated
from a standard curve against the control sample. The data were
obtained from four independent experiments each carried out in du-
plicate (mean þ S.E.M.).
FEBS 23092 9-12-99
C. Ettelaie et al./FEBS Letters 463 (1999) 341^344342
involved in prothrombinase complex assembly rather than
being a direct inhibitor of factor Xa.
3.4. Measurement of the e¡ect of TFPI254ÿ265 peptide on the
activation and activity of factor VII
Pre-incubation of TFPI254ÿ265 peptide (500 nM) with factor
VII (50 nM), prior to addition to tissue factor (200 nM) and
factor VII-de¢cient plasma, did not change the activity of the
enzyme (inhibition = 5% þ 7). In order to assess whether the
action of TFPI254ÿ265 peptide was directed to the proteolytic
activity of factor VIIa/tissue factor or the activation of factor
VII by interaction with tissue factor, tissue factor (200 nM)
and factor VII (200 nM) were incubated for 10 min in the
presence of 25 mM CaCl2, prior to addition of TFPI254ÿ265
peptide (500 nM) followed by a further 10 min incubation. In
a second experiment, tissue factor, factor VII and factor Xa
(100 nM) were pre-incubated for 10 min in the presence of 25
mM CaCl2, prior to addition of TFPI254ÿ265 peptide and a
further 10 min incubation. The samples were then assayed by
addition to factor VII-de¢cient plasma and measurement of
the clotting time. TFPI254ÿ265 peptide did not in£uence the
activity of factor VIIa (inhibition = 10% þ 8). In contrast, the
peptide was able to inhibit the activation of the pro-enzyme
(inhibition = 70% þ 8). This indicates the ability of the peptide
to inhibit the activation of factor VII, but not the activity of
pre-activated factor VIIa.
4. Discussion
There are two forms of TFPI detected in vivo [6,7], which
are identical in sequence with the exception that the lighter
truncated form does not possess the highly basic C-terminal.
The C-terminal truncated TFPI has a lower inhibitory poten-
tial than full-length TFPI, indicating that the C-terminal pep-
tide has a functional role against tissue factor activity [6,7].
Furthermore, although the two forms of TFPI have similar
abilities to inhibit factor Xa, the formation of the quaternary
complex tissue factor-factor VIIa-TFPI-factor Xa occurs
more readily with the full-length TFPI [8]. The reason for
the presence of the two forms of circulating TFPI with di¡er-
ent inhibitory potentials is as yet unknown, but may be sig-
ni¢cant in the proper control of haemostasis. Here, we suggest
a possible explanation for the disparity in the level and stabil-
ity of inhibition observed between full-length and truncated
TFPI.
It has been shown previously that full-length TFPI may
associate with LDL with a resultant reduction in the overall
activity of the complex towards tissue factor [9,15]. Recently,
Bridey et al. recorded a 2-fold enhancement of the speci¢c
activity of LDL-bound TFPI as compared to free TFPI,
although the nature of TFPI in the fractions was not deter-
mined [16]. However, since the concentration of plasma apo-
lipoprotein (apo) B-100 is approximately 50 times that of
TFPI, it is also possible that the tissue factor inhibition by
the LDL/LDL-TFPI may arise from the TFPI-free LDL only.
Indeed, a higher speci¢c activity of factor VIIa (factor VIIa
activity/factor VIIa antigen) (2.5^3-fold) has been observed in
patients with a L-lipoproteinemia [17], indicating that LDL
markedly attenuates factor VIIa activity. The ability of the
receptor binding domain of apo B-100 (residues 3147^3160)
to inhibit tissue factor arises from the direct interaction of
lysine residues within this domain with negative residues with-
in tissue factor (residues 58^66) was shown in earlier work
from this laboratory [12,18^21]. In comparison to the apo
B-1000-derived peptide [12], the ability of TFPI254ÿ265 peptide
to inhibit tissue factor was similar in magnitude. Alignment of
the two sequences revealed a number of identical (bold) and
similar (underlined) amino acids.
In the case of TFPI254ÿ265 peptide, we have now performed
a more extensive mutational analysis than was performed with
the apo B-100-derived peptide. Nevertheless it is still possible
to compare the e¡ects of the mutations in some of the key
sites, especially those at positions 7, 8 and 9 which are clearly
important in the inhibition of both TFPI254ÿ265 peptide and
apo B-100-derived peptides, although minor di¡erences occur.
Of particular note are the alanine substitutions of lysines 3151
and 3152 (positions 7 and 8 above) and asparagine 3153 (in
position 9) within the apo B-100-derived peptide, which re-
sults in large reduction of the inhibitory function of this pep-
tide [12]. Equally, the residue in position 10 was shown not to
be of signi¢cance in both cases. The lysines at positions 3, 5
and 12 in TFPI254ÿ265 peptide were also found to be essential,
but the importance of the equivalent amino acids in apo B-
100-derived peptide has yet to be established. We opted to
carry out mutational analysis of these amino acids in turn,
within the C-terminal peptide rather than within full-length
TFPI. Although the mutation of a single amino acid within
the C-terminal a¡ects the inhibitory potential of the TFPI,
this e¡ect would have been less evident since the intact Kunitz
domains were still active. Therefore, the e¡ect of the C-termi-
nal domain on the TFPI would only become easily detectable
when the whole C-terminal is missing, as in the natural trun-
cated form [6,7].
Aspartate 58 within the sequence of tissue factor is involved
in the binding [22,23] and activation of factor VII [24]. If this
Fig. 2. Time-course assay of the inhibition of the procoagulant ac-
tivity of PMA-treated THP-1 monocytic cells by EPIC peptide.
THP-1 monocytic cells were incubated with 10 nM PMA for 4 h.
The cells were then centrifuged and resuspended to 107 cells/ml in
phosphate-bu¡ered saline. Two-hundred Wl aliquots were incubated
with 50 Wl TFPI254ÿ265 peptide (100 (8), 150 (R) and 200 (F) nM
¢nal concentration) at 37‡C. A control peptide was also included in
the assay (not shown). The residual tissue factor activity was moni-
tored over 40. The percentage inhibition of tissue factor activity was
calculated against the control sample. The data were obtained from
three independent experiments (mean þ S.E.M.).
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domain is masked by these peptides, it would interrupt the
correct factor VII-tissue factor complex formation and subse-
quent factor VII activation. Therefore, full-length TFPI has a
dual action in inhibiting tissue factor directly, as well as the
activities of factor Xa and VIIa.
In conclusion, the novel anticoagulant property of a peptide
rich in basic amino acids (residues 254^265) within the C-
terminal of TFPI has been demonstrated acting on tissue fac-
tor and prothrombinase complex independently of the Kunitz
domains. An explanation is proposed for the disparity in the
abilities of full-length and C-terminal truncated TFPI to in-
hibit the extrinsic pathway of coagulation.
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Fig. 3. Time-course assay of the inhibition of the procoagulant ac-
tivity of factor Xa by TFPI254ÿ265 peptide. (a) One ml samples con-
taining TFPI254ÿ265 peptide (500 (F), 200 (R) and 100 (8) nM)
were mixed with factor Xa (100 nM). One-hundred Wl of the sam-
ples was removed immediately and assayed for factor Xa activity by
addition to factor Xa-de¢cient plasma in the presence of CaCl2 (25
mM) and measuring the clotting time. The rest of the sample was
incubated at 37‡C and further 100 Wl samples were removed at in-
tervals up to 40 min and measured as before. The activity was
measured against a standard curve and the percentage inhibition
calculated against the initial factor Xa activity. (b) One ml samples
containing TFPI254ÿ265 peptide (500 (E), 200 (O) and 100 (7) nM)
were mixed with factor V (1 WM). One-hundred Wl of each sample
was removed immediately and assayed for factor Xa activity by ad-
dition to factor V-de¢cient plasma, pre-activated by incubation (2
min) with tissue factor (200 nM) in the presence of CaCl2 (25 mM)
and measurement of clotting time. The rest of the sample was incu-
bated at 37‡C and further 100 Wl samples were removed at intervals
up to 40 min and measured as before. The activity was measured
against a standard curve and the percentage inhibition calculated
against the initial factor V activity. The data were obtained from
three independent experiments (mean þ S.E.M.).
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